News | May 28, 2014

WuXi PharmaTech Begins Operation Of New High-Potency API Laboratory

Shanghai, China /PRNewswire/ - WuXi PharmaTech (Cayman) Inc. (NYSE: WX), a leading pharmaceutical, biotechnology, and medical device R&D services company with operations in China and the United States, today announced that its manufacturing subsidiary, Syn-The-All Pharmaceutical Co., Ltd. (STA), has begun operation of a high-potency active pharmaceutical ingredient (HPAPI) laboratory in Shanghai, thereby adding HPAPI processing to its portfolio of services. The lab will support process development and clinical-trial supply of high-potency small molecules at kilogram scale.

"With the increasing use of HPAPIs in drug discovery and development, this new service augments WuXi's ability to provide highly efficient and cost-effective solutions for our partners worldwide," said Dr. Ge Li, Chairman and CEO of WuXi PharmaTech.

Technical inquiries regarding process development and clinical-trial supply of high-potency API materials can be made by contacting STAinfo@wuxiapptec.com.

About WuXi PharmaTech
WuXi PharmaTech (NYSE: WX) is a leading pharmaceutical, biotechnology, and medical device R&D outsourcing company, with operations in China and the United States. As a research-driven and customer-focused company, WuXi PharmaTech provides pharmaceutical, biotechnology and medical device companies with a broad and integrated portfolio of laboratory and manufacturing services throughout the drug and medical device R&D process. WuXi PharmaTech's services are designed to help its global partners in shortening the cycle and lowering the cost of drug and medical device R&D. The operating subsidiaries of WuXi PharmaTech are known as WuXi AppTec.

SOURCE: WuXi PharmaTech (Cayman) Inc.

Copyright 2014 PR Newswire. All Rights Reserved
Newsletter Signup
Newsletter Signup
Get the latest industry news, insights, and analysis delivered to your inbox.
Join your peers
By clicking Sign Me Up, you agree to our Terms and that you have read our Privacy Policy.